Events

As innovative drug delivery platforms beyond GalNac continue to emerge and novel chemical modifications are discovered, the potential for RNAi therapeutics to treat a plethora...

Molecular glue development continues to thrive, offering exciting opportunities to target previously undruggable proteins and treat a wide range of diseases. 2024 has seen a multitude...

CI's forum brings together government, manufacturers, patients, and payers to discuss patients access to the right drugs and provide a clear view of Canada’s pharmaceutical...

Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year,...

Propel Kinase Biology Understanding to Increase Selectivity, Overcome Resistance and Find the Optimal Combination Partner to Develop Best and First-in-Class Kinase Targeted Drugs...

Over the past 12 months, liquid biopsy testing has continued to revolutionize diagnostics and personalized medicine; from the integration of AI and automation to elevate liquid...

Accelerate collaboration and partnering across neurology and psychiatry pipelines and technologies, to reduce risk, validate technologies, and deliver better biodistribution of...

Immune tolerance offers a transformative approach to autoimmune diseases treatment and holds the power to modify the course of disease progression and significantly improve the...

Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources...

With RNA technologies receiving the Nobel Prize two years running, we are witnessing the mRNA industry make great strides as optimized analytics, critical quality control methodology...

As the cell and gene therapy (CGT) pipeline matures and new, exciting technologies scale into the clinic, the success of delivering the growing number of complex CGTs to patients...

Reuters Pharma USA 2025 will unite senior pharma leaders across commercial, marketing, medical affairs, patient engagement, market access, real world evidence and data for two...

In 2025, the spotlight is on neurodegenerative drug development, driven by the triumph of Lecanemab and Donanemab, coupled with rapid advancements to enable presymptomatic diagnosis...

Over the past year, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca, and...

Welcome to the 8th Gene Therapy Development Summit Transforming the Future of Gene Therapies for Rare and Common Diseases With 14 new gene therapy approvals in the last 18 months...